Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Braintree Laboratories, Inc.
Braintree Laboratories in-licenses rights to chemoprevention agent against colorectal cancer
April 8th, 2006
Braintree Laboratories, Inc., has in-licensed the global rights to develop and commercialize BLI-600, a patent protected compound that has shown significant promise as a chemoprevention agent, from INRA Transfert (IT), a subsidiary of National Institute for Agricultural Research (INRA), Paris, France. Under the terms of the agreement, Braintree Laboratories is responsible for the clinical development and worldwide registration of the compound for chemoprevention and/or treatment of colorectal cancer. The Foods & Cancer team of the joint research group ENVT-INRA Xenobiotics managed by Pr Denis Corpet, leader in the field of food and colon...
Source: Law & Health Weekly (2006-04-08)
|
